

Mark Lynch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11285540/publications.pdf>

Version: 2024-02-01

21
papers

14,872
citations

489802

18
h-index

759306

22
g-index

22
all docs

22
docs citations

22
times ranked

19475
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016, 375, 1856-1867.	13.9	3,845
2	BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. <i>Cancer Research</i> , 2004, 64, 7099-7109.	0.4	3,718
3	Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 835-844.	21.5	1,525
4	Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5. <i>Cancer Research</i> , 2006, 66, 11851-11858.	0.4	1,315
5	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3129-3140.	1.9	1,237
6	Regorafenib (BAY 734506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. <i>International Journal of Cancer</i> , 2011, 129, 245-255.	2.3	1,068
7	Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. <i>Oral Oncology</i> , 2018, 81, 45-51.	0.8	589
8	Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 561-574.	1.1	419
9	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1104-1115.	5.1	325
10	Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. <i>Blood</i> , 2016, 127, 2833-2840.	0.6	207
11	A Role for TLR4 in Clostridium difficile Infection and the Recognition of Surface Layer Proteins. <i>PLoS Pathogens</i> , 2011, 7, e1002076.	2.1	131
12	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. <i>Clinical Cancer Research</i> , 2019, 25, 5221-5230.	3.2	115
13	A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. <i>Oral Oncology</i> , 2017, 73, 138-146.	0.8	90
14	CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. <i>Oncologist</i> , 2018, 23, 1079-1082.	1.9	70
15	Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , 2019, 125, 3208-3218.	2.0	64
16	Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. <i>Molecular Cancer</i> , 2009, 8, 27.	7.9	45
17	Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2016, 175, 448-456.	1.2	39
18	Surface layer proteins isolated from Clostridium difficile induce clearance responses in macrophages. <i>Microbes and Infection</i> , 2014, 16, 391-400.	1.0	20

#	ARTICLE	IF	CITATIONS
19	Surface layer proteins from virulent Clostridium difficile ribotypes exhibit signatures of positive selection with consequences for innate immune response. BMC Evolutionary Biology, 2017, 17, 90.	3.2	19
20	Profiling Humoral Immune Responses to Clostridium difficile-Specific Antigens by Protein Microarray Analysis. Vaccine Journal, 2015, 22, 1033-1039.	3.2	12
21	The EGF/TGF β response element within the TGF β promoter consists of a multi-complex regulatory element. Oncogene, 1999, 18, 5923-5935.	2.6	9